Quantcast

Latest MedImmune Stories

2014-04-02 08:34:05

NES ZIONA, Israel, April 2, 2014 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd (TASE: BNDX), developer of a universal flu vaccine, announced today that its Board of Directors has approved initiation of the process for listing the Company's shares for trading in the US through American Depository Receipt (ADR). The Company will act to register an ADR Level 1 Over-The-Counter (OTC), which does not include the option for public offerings in the US (without additional registration)....

2014-03-31 08:28:42

-- Conference Call Today, March 31, 2014, at 10:00 a.m. (EDT) -- ROCKVILLE, Md., March 31, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, today reported financial results for the year ended December 31, 2013 and provided operational highlights. http://photos.prnewswire.com/prnvar/20130522/MM19465LOGO Recent Operational Highlights...

2014-03-26 04:21:13

LONDON and BOSTON, March 26, 2014 /PRNewswire/ -- Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, notes that a company presentation to be given by its Chief Executive Officer, Malcolm Weir, at BioCentury Future Leaders in the Biotech Industry [https://www.biocentury.com/conferences/futureleaders/dates ] on 28 March 2014 will be webcast live. The presentation will take place at 9.30am ET in room 302/303 at the Millennium Broadway...

2014-03-17 08:29:07

HOUSTON, March 17, 2014 /PRNewswire-USNewswire/ -- The University of Texas MD Anderson Cancer Center and MedImmune, the global biologics research and development arm of AstraZeneca, will collaborate through MD Anderson's Moon Shots Program to develop therapies that unleash patients' immune systems to attack their cancers. "Our collaboration with MedImmune, a leader in the field of immunotherapy, will draw on the strengths of both institutions to push ahead for more effective...

2014-02-25 20:21:36

DUBLIN, February 26, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/jnwqq6/h1n1_vaccines) has announced the addition of the "H1N1 Vaccines - Global Strategic Business Report" [http://www.researchandmarkets.com/research/jnwqq6/h1n1_vaccines ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) This report analyzes the Global market for H1N1 Vaccines in US$ Million. The report provides...

2014-01-30 08:32:21

AVP-825 uses novel Breath Powered(TM) drug delivery to treat migraine YARDLEY, Pa., Jan. 30, 2014 /PRNewswire/ -- A New Drug Application (NDA) was submitted on Monday January 27, 2014 to the U.S. Food and Drug Administration for AVP-825, a product using OptiNose's innovative closed-palate Breath Powered intranasal delivery system to deliver low-dose sumatriptan powder for the acute treatment of migraine. The NDA submission is based on a series of laboratory and clinical studies...

2014-01-29 00:20:55

SINGAPORE and ZURICH, January 29, 2014 /PRNewswire/ -- Singapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced that their influenza vaccine (gH1-Qbeta) met its primary end point for immunogenicity (seroconversion based on haemaglutination inhibition titres according to FDA criteria) in the Phase 1 clinical trial in healthy Asian volunteers. The induced immune response showed good cross-reactivity to recent...

2014-01-27 08:27:07

-- Joseph Sliman, M.D., M.P.H., Joins Team as Senior Vice President, Clinical & Regulatory Affairs -- ROCKVILLE, Md., Jan. 27, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of product candidates focused on the prevention and treatment of serious infectious and other diseases, announced today that Joseph Sliman, M.D., M.P.H., joined the team and will assume the role of Senior Vice President, Clinical & Regulatory Affairs, previously held by Carol...

2014-01-23 04:21:26

LONDON and BOSTON, January 23, 2014 /PRNewswire/ -- Stabilised GPCR (StaR(R)) Proteins Delivered For All Nominated Targets Heptares Therapeutics, the leading GPCR structure-guided drug discovery and development company, has successfully completed the research phase of its antibody drug discovery collaboration with MedImmune, the global biologics research and development arm of AstraZeneca. In achieving this milestone, Heptares has delivered StaR(R) proteins...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'